Bonesupport Holding Valuation

Q: What is the Fair Price of 0RQO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

0RQO (SEK313.08) is trading above our estimate of [[fair value]] (SEK304.76)

Is 0RQO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0RQO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0RQO (SEK313.08) is trading above our estimate of fair value (SEK304.76)

Significantly Below Fair Value: 0RQO is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0RQO?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 0RQO. This is calculated by dividing 0RQO's market cap by their current preferred multiple.
What is 0RQO's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	SEK 20.39b

0RQO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	27.6x
Enterprise Value/EBITDA	263.2x
PEG Ratio	2.3x

Price to Earnings Ratio vs Peers

How does 0RQO's PE Ratio compare to its peers?

The above table shows the PE ratio for 0RQO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	96.2x
GNS Genus	167.2x	39.4%	UK£1.3b
BVXP Bioventix	23.8x	5.2%	UK£206.2m
ERGO Ergomed	46.7x	14.2%	UK£701.1m
MNKD MannKind	146.9x	39.4%	US$1.8b
0RQO Bonesupport Holding	70.6x	31.2%	SEK 20.4b

Price-To-Earnings vs Peers: 0RQO is good value based on its Price-To-Earnings Ratio (70.6x) compared to the peer average (111.7x).

Price to Earnings Ratio vs Industry

How does 0RQO's PE Ratio compare vs other companies in the European Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	36.7%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	36.7%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: 0RQO is expensive based on its Price-To-Earnings Ratio (70.6x) compared to the European Biotechs industry average (26.9x).

Price to Earnings Ratio vs Fair Ratio

What is 0RQO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0RQO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	70.6x
Fair PE Ratio	36.9x

Price-To-Earnings vs Fair Ratio: 0RQO is expensive based on its Price-To-Earnings Ratio (70.6x) compared to the estimated Fair Price-To-Earnings Ratio (36.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0RQO forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	SEK 299.80	SEK 323.33 +7.8%	9.6%	SEK 350.00	SEK 280.00	n/a	3
Sep ’25	SEK 301.59	SEK 323.33 +7.2%	9.6%	SEK 350.00	SEK 280.00	n/a	3
Aug ’25	SEK 291.23	SEK 323.33 +11.0%	9.6%	SEK 350.00	SEK 280.00	n/a	3
Jul ’25	SEK 271.41	SEK 297.67 +9.7%	4.6%	SEK 313.00	SEK 280.00	n/a	3
Jun ’25	SEK 254.40	SEK 292.67 +15.0%	5.0%	SEK 313.00	SEK 280.00	n/a	3
May ’25	SEK 226.00	SEK 292.67 +29.5%	5.0%	SEK 313.00	SEK 280.00	n/a	3
Apr ’25	SEK 223.99	SEK 273.67 +22.2%	4.6%	SEK 285.00	SEK 256.00	n/a	3
Mar ’25	SEK 195.83	SEK 257.00 +31.2%	7.2%	SEK 280.00	SEK 235.00	n/a	3
Feb ’25	SEK 203.22	SEK 257.00 +26.5%	7.2%	SEK 280.00	SEK 235.00	n/a	3
Jan ’25	SEK 188.50	SEK 245.50 +30.2%	4.3%	SEK 256.00	SEK 235.00	n/a	2
Dec ’24	SEK 175.71	SEK 245.50 +39.7%	4.3%	SEK 256.00	SEK 235.00	n/a	2
Nov ’24	SEK 148.29	SEK 166.50 +12.3%	3.9%	SEK 173.00	SEK 160.00	n/a	2
Oct ’24	SEK 127.50	SEK 166.50 +30.6%	3.9%	SEK 173.00	SEK 160.00	n/a	2
Sep ’24	SEK 123.70	SEK 166.50 +34.6%	3.9%	SEK 173.00	SEK 160.00	SEK 301.59	2
Aug ’24	SEK 144.89	SEK 166.50 +14.9%	3.9%	SEK 173.00	SEK 160.00	SEK 291.23	2
Jul ’24	SEK 127.60	SEK 154.00 +20.7%	9.1%	SEK 168.00	SEK 140.00	SEK 271.41	2
Jun ’24	SEK 118.30	SEK 154.00 +30.2%	9.1%	SEK 168.00	SEK 140.00	SEK 254.40	2
May ’24	SEK 102.22	SEK 141.50 +38.4%	18.7%	SEK 168.00	SEK 115.00	SEK 226.00	2
Apr ’24	SEK 83.50	SEK 141.50 +69.5%	18.7%	SEK 168.00	SEK 115.00	SEK 223.99	2
Mar ’24	SEK 86.58	SEK 141.50 +63.4%	18.7%	SEK 168.00	SEK 115.00	SEK 195.83	2
Feb ’24	SEK 87.85	SEK 123.50 +40.6%	6.9%	SEK 132.00	SEK 115.00	SEK 203.22	2
Jan ’24	SEK 80.45	SEK 123.50 +53.5%	6.9%	SEK 132.00	SEK 115.00	SEK 188.50	2
Dec ’23	SEK 85.77	SEK 121.00 +41.1%	9.1%	SEK 132.00	SEK 110.00	SEK 175.71	2
Nov ’23	SEK 88.00	SEK 121.00 +37.5%	9.1%	SEK 132.00	SEK 110.00	SEK 148.29	2
Oct ’23	SEK 73.35	SEK 91.00 +24.1%	15.4%	SEK 105.00	SEK 77.00	SEK 127.50	2
Sep ’23	SEK 68.00	SEK 91.00 +33.8%	15.4%	SEK 105.00	SEK 77.00	SEK 123.70	2

Analyst Forecast: Target price is less than 20% higher than the current share price.